Sign In
Buy BNGO
$1.30
+0.0400 (+3.17%)
At Close: Jun 03, 2026
Crude Oil Rises Over 2%; Bionano Genomics Shares Plunge
01:41pm, Tuesday, 16'th Sep 2025
U.S. stocks traded mostly lower midway through trading, with the Dow Jones index falling more than 150 points on Tuesday.
SAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that an issue of the book series Methods in Molecular Biology dedicated to studies of the catastrop
CMS Posts Preliminary Payment Determination for New Category I CPT Code Covering Use of OGM for Constitutional Genetic Disorders
07:00am, Monday, 15'th Sep 2025
SAN DIEGO, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) offering CLIA-certified laboratory developed tests (LDTs) based o
Despite Fast-paced Momentum, Bionano Genomics (BNGO) Is Still a Bargain Stock
05:36pm, Monday, 08'th Sep 2025
Bionano Genomics (BNGO) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stock
Bionano to Present at the H.C. Wainwright 27th Annual Global Investment Conference
08:00am, Monday, 25'th Aug 2025
SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano's president and chief executive officer, will present at the H.C. Wai
Bionano Genomics (BNGO) Is Attractively Priced Despite Fast-paced Momentum
09:50am, Friday, 22'nd Aug 2025
Bionano Genomics (BNGO) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are sti
Bionano Genomics, Inc. (BNGO) Q2 2025 Earnings Call Transcript
04:37am, Friday, 15'th Aug 2025
Bionano Genomics, Inc. (NASDAQ:BNGO ) Q2 2025 Earnings Conference Call August 14, 2025 4:30 PM ET Company Participants Robert Erik Holmlin - President, CEO, CFO & Director Conference Call Participants
Bionano Reports Second Quarter 2025 Results and Highlights Recent Business Progress
04:01pm, Thursday, 14'th Aug 2025
SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the second quarter ended June 30, 2025. “We continued to execute on our new st
Bionano Announces Publication Showing Utility of Optical Genome Mapping in Clinical Research of Infant & Toddler T-ALL
08:00am, Thursday, 07'th Aug 2025
SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a peer-reviewed publication from a team led by Manon Delafoy from the Institut Necker Enfants Malades
Bionano to Present at the Canaccord Genuity 45th Annual Growth Conference
08:00am, Wednesday, 06'th Aug 2025
SAN DIEGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano's president and chief executive officer, will present at the Canaccor
Bionano to Report Second Quarter 2025 Financial Results and Host a Conference Call Webcast on August 14, 2025
04:05pm, Thursday, 31'st Jul 2025
SAN DIEGO, July 31, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Thursday, August 14, 2025, at 4:30 p.m. East
SAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) that offers CLIA-certified laboratory developed tests (LDTs) based
Bionano Genomics, Inc. (BNGO) Q1 2025 Earnings Call Transcript
07:46pm, Wednesday, 14'th May 2025
Bionano Genomics, Inc. (NASDAQ:BNGO ) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants David Holmes - IR Erik Holmlin - CEO and Principal Financial Officer Conference Call
Bionano Reports First Quarter 2025 Results and Highlights Recent Business Progress
04:01pm, Wednesday, 14'th May 2025
SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the first quarter ended March 31, 2025. “The first quarter of 2025 represents t
In 58% or 303 of 519 cases, optical genome mapping (OGM) revealed somatic aberrations that were not detected by the standard cytogenetic workup (SCGW), including Tier 1, Tier 2 and Tier 3 structural v
